Table 2

The clinically investigated group - diagnosis and levels of CSF biomarkers, median (range)
FTD (n=34) bvFTD (n=23) SD (n=7) PNFA (n=4) AD (n=20) Controls(n=26) Significance
NFL (ng/L) 844 (250–2760) 770 (250–2760) 1340 (580–1940) 455 (250–1040) 415 (250–860) 250 (250–710) FTD> AD p<0.001 SD>AD p<0.001 FTDbv> AD p<0.001
Aβ42 (ng/L) 555 (140–1130) 570 (260–1130) 595(360–1110) 215 (140–380) 285 (140–460) NA FTD>AD p<0.001
Tau (ng/L) 355 (150–820) 280 (160–750) 385(180–770) 610 (150–820) 630 (230–2290) NA AD>FTD p<0.001
p-tau (ng/L) 49 (23–115) 45(29–82) 55 (23–92) 88 (45–115) 87 (42–237) NA AD<FTD p<0.001
Albumin ratio 0.00755 (0.0025-0.0346) 0.00765 (0.0043-0.0346) 0.00655 (0.0051-0.0134) 0.0058 (0.0025-0.0081) 0.00665 (0.0033-0.0099) NA Non-significant

NA Not analysed.

Landqvist Waldö et al.

Landqvist Waldö et al. BMC Neurology 2013 13:54   doi:10.1186/1471-2377-13-54

Open Data